Entity

Time filter

Source Type

Mumbai, India

Patent
IPCA LABORATORIES Ltd | Date: 2013-09-20

The present invention relates to a novel pharmaceutical composition having enhanced bioavailability through improved aqueous dissolution of poorly water soluble drugs, and to a method for preparing it. The invention more particularly relates to an oral pharmaceutical composition containing active ingredients of poor aqueous solubility, more specifically, antiparasitic and antipneumocystic drug Atovaquone alone or in combination with Proguanil.


Patent
IPCA Laboratories Ltd | Date: 2013-08-07

The present invention relates to a method of ameliorating the drawbacks of anti-platelet drug named clopidogrel. The method of the present invention comprises administration of an (S)oxo-clopidogrel or its derivative of the Formula IIA in its free or pharmaceutically acceptable salt form for alleviating the symptoms of thrombosis or embolism by inhibiting blood platelet aggregation. Compositions for use in such methods are also provided.


Patent
IPCA LABORATORIES Ltd | Date: 2013-10-03

New compounds, namely, (7aS,2S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases.


Patent
IPCA Laboratories Ltd | Date: 2014-03-06

A method for treatment and/or prophylaxis of Kidney Diseases of Non-inflammatory etiology in mammals is described herein. The method comprises administering Hydroxychloroquine, its enantiomer or a pharmaceutically acceptable salt thereof or its combinations with at least one drug selected from the group of angiotensin receptor blockers and angiotensin converting enzyme inhibitors. More particularly, a method is provided for treatment and/or prophylaxis of Diabetic Kidney Disease in mammals, which comprises administering a therapeutically effective amount of Hydroxychloroquine, its enantiomer or a pharmaceutically acceptable salt thereof or its combinations with an angiotensin receptor blockers or an ACE inhibitors. Pharmaceutical compositions are provided for the above treatment. Provided is the use of Hydroxychloroquine, its enantiomer or a pharmaceutically acceptable salt thereof or its combinations with at least one drug selected from the group of angiotensin receptor blockers and ACE inhibitors, wherein in the treatment and/or prophylaxis of Kidney Diseases of Non-inflammatory etiology in mammals.


Patent
IPCA LABORATORIES Ltd | Date: 2013-08-01

New compounds, namely, (7aS,2S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases.

Discover hidden collaborations